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DMPA INJECTABLE USE:
Findings from the 21-Month DMPA Monitoring Study

INTRODUCTION
This report presents the results of the DMPA Monitoring Study undertaken by the
Population Council, Manila as a technical assistance project for the DMPA
Reintroduction Program of the Department of Health (DOH). The primary objective
of the study is to provide data on DMPA utilization and continuation rates, as may
be used to project the logistical needs of the program during the next three years.
Data on the availability of DMPA supplies and on IEC (information, education and
communication) materials relating to DMPA were also monitored to provide some
measure of the effectiveness of the program's distribution system.
The study covers a 21-month observation period from April 1994 to December 1995
and concentrates on 1,379 DMPA-dispensing health facilities in the ten local
government units (LGUs) covered by Phase I of the DMPA Reintroduction Program.
These LGUs are Baguio City, Quezon City, Laguna, Pangasinan, Iloilo City, Cebu,
Davao City, Davao del Sur, South Cotobato and Surigao del Sur. Pangasinan and
Cebu were by far the largest of these, being able to account for nearly half of all the
facilities covered by this report (see Figure 1). Data are based upon reports received
as of February 29, 1996 from at least 80% of the total DMPA-dispensing facilities in
these pilot LGUs.
An earlier report (Final Report A) was prepared in August 1995 covering the months
from April 1994 to June 1995.2 This report (Final Report B) will also integrate
2This

report (Population Council, Manila, 1995) was termed as "final" because the study was
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information generated from monitoring reports for the period July to December
1995. The same 1,379 DMPA-dispensing facilities were asked to submit reports to
the Population Council during this six-month period.
Figure 1

originally conceptualized as incorporating a fifteen-month data collection component. A request
was subsequently made by the DMPA Task Force, however, to extend the study by another six
months in order to provide a stronger empirical basis for projecting future trends.
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OBJECTIVES OF THE MONITORING STUDY

The primary objective of the monitoring study has been to obtain information on
the level and patterns of DMPA use in the ten pilot LGUs to serve as a basis for
determining logistical needs up to 1998. Other goals of the study focussed on the
aim of collecting information on the DMPA drop-out problem, on the effectiveness
of the program's system for distributing DMPA-related supplies, and on inter-LGU
differentials in program performance.

METHODOLOGY
The methodology adopted for the additional 6-month observation period (July to
December 1995) was similar to the procedure utilized during the first part of the
study. For example, a "reporting officer" was again designated for each of the 1,379
dispensing facilities. A distinction can be made, however, with regard to the
frequency with which reports were to be submitted. During the first fifteen months
of the project, these were to be sent to the Population Council office on a monthly
basis. In comparison, reports were to be prepared and submitted every three
months during the final six-month period. A revised monitoring form was designed
for this purpose (see Figure 2).3
Data from the monitoring forms were encoded and data processed at the Population
Council office. Two quarterly reports (Fifth and Sixth Progress reports respectively)
were prepared covering the months July-September and October-December, 1995.
3Worth

noting, though, is the fact that many of the reporting officers continued to use the original
version of the reporting form, i.e. to submit their reports on a monthly basis. As a result, it was still
possible to compute monthly reporting rates for the participating facilities (see below, Figures 3 and 4).
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Source of Data
Data for this report are based on monitoring forms for April 1994 to December 1995,
which had been received at the Population Council office as of February 29, 1996.
During the twenty-one month observation period, all except thirty-nine of the 1,379
DMPA service delivery outlets submitted at least one monthly report. Submission
rates were highest during the first nine months of the study, with an average
reporting rate of 91 percent. This fell to 82 percent during the next six months and
then again to 72 percent for the period July-December 1995. Figure 3 shows trends
over time in this regard.

Figure 3
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The lowest reporting rate occurred for December 1995, the last observation month,
when only 64 percent of the facilities submitted their report. This was due largely to
the very low reporting rates turned in at this time by such big provinces as Laguna,
Davao Sur and Cebu (see Figure 4). Submission rates for all other LGUs were
higher than 80 percent at this time.

Figure 4
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RESULTS OF THE MONITORING STUDY
A. DMPA Utilization
A total of 157,662 DMPA injections were reported to have been dispensed in the ten
pilot LGUs within the 21-month observation period between April 1994 and December
1995. As shown in Figure 5, a total of 62,736 (or 39.8 percent) of these were given as first
injections to new DMPA acceptors, while 94,926 (or 61.2 percent) were given as
reinjections. Reinjections include second, third, fourth, fifth, and sixth injections.

Figure 5
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Figure 6

Figure 6 shows that levels of DMPA utilization were low during the first quarter
(April-June 1994). Training sessions for service providers were still ongoing at this time.
A total of only 1,867 injections were dispensed during this period.
A significant increase can be noted during the second quarter of the study, particularly
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during the month of August when a total of 7,034 injections were reported to have been
dispensed.

Utilization levels continued to increase to 8,732 during the month of

November and then to 10,468 injections by February 1995. The number of injections
then declined slightly during March and April although a small increase was registered
by May when the total number of injections again exceeded 10,400. A gradual decline
then set in during the remaining seven months, so that they reached a low point of 8,077
injections as of December, the last month included in the observation period.
These data raise an important question. Should the eventual decline in DMPA use be
attributed to the fact that a decreasing number of facilities were submitting their
monitoring forms during the latter half of this study or has there been an actual falling
off in the popularity of this family planning method? One way to answer this question
is to look at trends over time in the number of DMPA injections given out per reporting
facility. Should it prove true that this statistic has been increasing or at least remaining
steady during this period, the most likely explanation for the above findings would
probably be that they are largely an artifact of the reduced submission rates experienced
during the course of the study.
Figure 7 allows us to examine this issue. It shows that the highest monthly average
injections per facility was 9.7 during the month of August 1995. Per facility injection
levels during the next four months hovered around 9.1, a level which was still
somewhat higher than those which were generally reached during 1994 and the first
half of 1995. The major reason for the apparent decline in DMPA use must therefore be
attributed to the reporting factor, i.e., the decline over time in the number of facilities
willing to submit their monitoring forms.

9

Figure 7

Altogether, facilities in the pilot LGUs averaged about 3 or 4 injections per month
during the first quarter (i.e., the training period). This increased to about 6 or 7
injections per facility during the second quarter, 7 or 8 injections during the third
quarter, and 9 injections after that. For the whole 21-month observation period, the
program dispensed an average of 7.5 injections per facility per month.
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Figure 8

Figure 8 reveals that overall levels of DMPA utilization were reported to be highest
in Pangasinan and lowest in Iloilo City. Health facilities in Pangasinan recorded a
total of 43,254 injections within the 21-month period as compared to only 1,863
injections in Iloilo City.

Cebu province ranked second with a total of 29,819

injections while Davao Sur recorded 19,458.
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The above figures are affected, to some extent, by the larger base populations and
number of facilities found in such provinces as Pangasinan and Cebu. We have
therefore again used per facility statistics to control for this factor. The resulting data
(shown in Figure 9) reveal that, in terms of the average number of monthly acceptors
per facility, it is Quezon City that showed the highest output, with a mean level of
17.6 monthly injections over the 21-month observation period. Baguio City ranked
second with an average of 15.3 injections dispensed per facility per month. While
these figures might at first be taken to indicate that urban-based facilities are the best
able to attract large numbers of DMPA users, it is interesting to note that one of the
two other chartered cities in our sample of LGUs (i.e., Iloilo City) ranked lowest in
this regard, with a monthly average of only 3.1 injections.

13

Figure 9

Among the remaining LGUs, the provinces of Cebu and Davao Sur along with
Davao City had an average of 9 or more injections per month. South Cotabato was
lower still at 7.5 while Pangasinan, which had recorded the highest cumulative total
injections among the LGUs, and Surigao del Sur both averaged only 6.6 injections
per facility per month.
As a whole, the sample cities averaged 11.6 injections per facility per month while
the provinces averaged 7.6 injections per facility per month.

14

B. DMPA Acceptance
Findings discussed above refer to the total number of DMPA injections. Let us now
disaggregate these figures into their two major components; i.e., DMPA acceptors
(first injections) and DMPA reinjections. Figure 10 initiates this portion of the
analysis by providing data on the number of first injections.
In general, the total number of DMPA acceptors (or first injections) in the pilot LGUs
was low during the first quarter but increased significantly in August 1994, after the
completion of the training sessions for service providers. This month recorded the
highest number of acceptors within the 21-month period (6,730).

This figure

thereafter declined noticeably to a level less than one third as large (1,864) as of
December 1995. Overall trends in this regard are shown in Figure 10.

15

Figure 10

16

From the August 1994 high of 6,730 first injections, the total number of acceptors
dropped to an average of about 4,000 per month during the third quarter. This later
declined further to roughly 3,700 and 2,800 acceptors each month as of the fourth
and fifth quarters, respectively. During the six-month extension period of the study
additional declines were noted with the monthly averages at this time being about
2,500 first injections for July-September 1995 and 2,000 acceptors during October,
November and December of that same year.

The magnitude of this decline indicates that it may well be due to more than just a
matter of reduced submission rates. One way of checking this supposition is to
examine the average number of first injections per facility. As shown in Figure 11,
these figures indicate that there has indeed been a secular decline in the number of
women accepting DMPA. For example, an average of about 5 acceptors were being
noted each month by the reporting facilities during the period July to October 1994.
During the next five months this figure fell to about 3.5 DMPA acceptors per month
followed by nine straight months with averages below 3.0 acceptors. The average
for December 1995 (the last month of the study) was only 2.1, the lowest figure
recorded during the 21-month period covered by the study.
These findings do not speak well for the prospects that DMPA will capture a large
segment of Philippine family planning market. It seems that the demand for new
injections was already going into a major decline before the reintroduction program
had completed a year of operation. In attempting to explain this pattern, we may
point to the hypothetical importance of two different factors. One possibility is that
there is a sort of "ceiling effect" operating here; i.e., that only a maximum of 5 to 10
percent of all married women of reproductive age in the Philippines would ever be
likely or interested to accept DMPA.4 A second hypothesis worth considering,
3

Final Report A (Population Council, Manila, 1995, Figure 32) gives an estimate DMPA

17

though, is that the reintroduction program itself began to "lose steam" after the first
few months, with the result that fewer and fewer women were ever being informed
about their option to use this FP method. Further research will be needed to
determine the comparative validity of these two explanations.
Figure 11

acceptors in the ten LGUs (as of June 1995) at approximately 3 percent of all MWRAs.
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The LGUs which recorded the highest and lowest cumulative total injections
dispensed during the twenty one-month observation period were the same ones
recording the highest and lowest numbers of DMPA acceptors. Findings show that
Pangasinan had the highest cumulative total of DMPA acceptors at 16,922 while
Iloilo City turned in the lowest cumulative output with only 779 acceptors during
the entire study period (please see Figure 12).
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Figure 12

However, while Pangasinan may have had the highest cumulative total in terms of
new acceptors enrolled in the program, Figure 13 shows that its average monthly
output was only 2.6 acceptors per facility. This was twice higher than Iloilo City
which had the lowest average output of 1.3 acceptors per facility per month.
Quezon City and Baguio City recorded the highest average number of DMPA
acceptors at about 7.3 and 5.5 per facility per month. On the whole, the ten pilot
LGUs averaged 3.2 new acceptors per facility per month.

20

Figure 13

Urban-based DMPA dispensing facilities accounted for about 5 acceptors per facility
per month while those in the provinces accounted for 3 acceptors per facility per
month .

21

C. DMPA Reinjections
The total number of reinjections increased significantly from January to September
1995. This increase, which is depicted in Figure 14, is due largely to the inclusion of
the third, fourth, and fifth injections at this time. A slight decline in the number of
reported

reinjections was observed during the last three months of the study

(October-December 1995). An analysis of the monthly averages for all reporting
facilities, however, shows that in this case the average number of reinjections per
reporting facility remained somewhat above average at this time when compared to
the study as a whole. The above decline may therefore be attributed to the reduced
submission rates experienced at that time.

22

Figure 14
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Again, Pangasinan recorded the highest number of reinjections dispensed during
the 21-month period while Iloilo City had the lowest. Facilities from the provinces
accounted for 80 percent of all DMPA reinjections whereas 20 percent came from
city-based facilities. In terms of reinjections per facility per month, though, those
from the cities performed slightly better at 6.9 reinjections per facility per month
while those from the provinces recorded only 4.6.

D.

DMPA Continuation/Reinjection Rates

To determine the DMPA continuation/reinjection rate, the actual number of
reinjections dispensed during a particular month was compared with the number of
reinjections expected to be given at this time. Reinjections included all second, third
fourth, fifth and sixth injections. Expected reinjections for a particular month were
equivalent to the total number of injections dispensed three months before, while
actual reinjections were those recorded for the month in question. Figure 15 shows
the comparison between the expected and the actual number of reinjections from
October 1994 to December 1995.
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Figure 15
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It is shown in Figure 16 that the reinjection rates for October and November 1994
were only a little more than 68 percent. A steady increase in reinjection rates was
then observed for the next four months as again followed by a continous decline
from April to June 1995. Although reinjection rates improved during the sixth
quarter (August to September), these again declined to as low as 61.9 percent during
November 1995.

Figure 16

Overall, the DMPA reinjection rate was 71.3 percent as shown in Figure 17. Of the
130,620 reinjections expected to be given between October 1994 to December 1995, a
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total of only 93,123 reinjections were actually dispensed.

Figure 17

Note however, that this approach to computing the DMPA reinjection rate for each
month lumps together the second, third, fourth and fifth injections. Hence, duration
of use and reinjection rates per injection could not be ascertained. This particular
limitation was due to the fact that the DMPA monitoring form, as originally
designed, failed to distinguish among these different durations of use (i.e., first,
second, third and fourth reinjection).
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E.

Current Users of DMPA

The proportion of all DMPA acceptors who were still current users as of the end of
this study's observation period was computed by adding the number of new
acceptors (first injections) and reinjections as of December 1995 to the number of
new and returning acceptors (total injections) for the two previous months. Given
that the effectivity of DMPA lasts for three months, women who have been injected
(or reinjected) during the preceding two months were also included. By comparing
the number of current users at the end of the observation period with the total
number of DMPA acceptors recorded throughout the entire study period, the
percentage of all acceptors who were still using this FP method can be ascertained.
Data in Figure 18 show that, of the 62,736 DMPA acceptors in the ten pilot LGUs,
only 25,175 were still using DMPA as of December 31, 1995. The overall proportion
of current users is therefore about 40 percent.

23

Figure 18

24

Current user rates varied per LGU. As shown in Figure 19, Baguio City showed the
highest current user rate.

Notice, however, that the low reporting LGUs --

specifically Laguna, Davao Sur and Cebu -- also recored low current user rates. It is
therefore likely that these estimates have been adversely affected by the data
retrieval problem discussed earlier.

Figure 19
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F.

Contribution of the Initial Implementation of the DMPA
Reintroduction Program to the Philippine FP Program

In this section we present data on the proportion of all MWRAs who adopted
DMPA so as to give some indication of the "impact" of the first phase of the DMPA
reintroduction program to the national FP program. At first glance, this would as
yet appear to be relatively minor. Data in Figures 20 and 21 thus show that, of the
estimated 1.9 million MWRA in the ten pilot LGUs, only 3.3 percent had accepted
DMPA during the observation period whereas an even smaller proportion (about
1.4 percent) were still using it as their FP method as of December 1995.
It should be noted that prior to the DMPA reintroduction program, only one-tenth of
1 percent (0.1 percent) of all Philippine women of reproductive age were using
DMPA. In that sense the current user level of 1.4 percent does show a definite,
though minimal, program impact, at least as far as the pilot LGUs are concerned. It
would appear in fact that the program was able to increase the level of injectable use
by about 1.3 percent.
In a follow-up survey of approximately 900 DMPA acceptors from nine of the pilot
LGUs, Patron and Palabrica-Costello (1995, Table 7a) found that 27.3 percent of
DMPA acceptors had never previously used any other form of FP. As a minimum
estimate,
therefore, we can say that the reintroduction program increased the current level of
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FP use in the pilot LGUs by approximately 0.4 percent.4

Figure 20

4That is, we are assuming in this case that 27.3 percent of DMPA acceptors would not be
using FP as of December 31, 1995 because they were not favorable towards any method other
than DMPA. We thus multiply 1.4 percent by .273 and get .003822, which rounds to 0.4 percent.
Note that this is probably an underestimate since it ignores the contribution made by DMPA
towards attracting FP dropouts (i.e., those past users of some other method who were not using
any method when they decided to have their first DMPA injection) back to the program.
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Figure 21
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G.

Availability of DMPA Supplies

The study also monitored the availability of DMPA vials, syringes and needles at the
health facilities covered by Phase I of the reintroduction program. Using the DMPA
monitoring form, service providers were asked to log the remaining stock of vials,
syringes and needles in the facility as of the end of each reporting month. This
information may be used in order to determine if there is an adequate stock in the
facility for the next three to six months as well as to see if there are discrepancies in
the number of vials vis-a-vis syringes and needles.
As of December 31, 1995, there was still a total of 30,666 vials and 30,737
syringes/needles in the health facilities which submitted a report on this. This
represents an average stock of 36 DMPA vials and 36 syringes/needles per reporting
health facility.
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Figure 22

The greatest numbers of unused vials and syringes were generally found in the
larger LGUs, e.g. Cebu, Quezon City and Pangasinan (Figure 22). In comparison,
Figure 23 shows that the greatest numbers of vials/syringes on a per facility basis
were found in Quezon City, Cebu and Baguio, all with 70 or more per facility.
Davao del Sur, Pangasinan and Surigao del Sur all fared more poorly in this regard
with averages of less than 20 vials/syringes per facilty.

These figures also

demonstrate that discrepancies in the average number of vials vis-a-vis the number
of syringes/needles were generally negligible. This would appear to indicate that
the DMPA syringes and needles are not being used for purposes other than that for
which they had been originally intended.

30

Figure 23
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Figure 24

The reported number of average stocks per facility in each LGU was compared to
the number of stocks which the LGU is expected to maintain by the DOH (i.e. the
minimum number of vials needed to service the local area population). Figure 24
shows the result of this comparison and indicates that most of the LGUs had an
adequate supply of DMPA vials as of December 31, 1995.

Supply shortages,

however, could be noted in Pangasinan, Davao City and Davao Sur.
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H.

Availability of DMPA IEC Materials

The study also monitored the availability of IEC materials, particularly the presence
of DMPA reminder cards and leaflets in the pilot facilities. These data are presented
in Figures 25 and 26.

Figure 25
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Figure 26

As of 31 December 1995, 27.9 percent of the reporting facilities no longer had any
reminder cards. LGUs which experienced a widespread shortage of reminder cards
included Surigao Sur (68.7%), South Cotabato (56.6%) and Cebu (53.5%).
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Figures 27 and 28 indicate that shortages of DMPA leaflets were also experienced by
a large proportion of the health facilities. As of 31 December 1995, 30.8 percent of
the reporting health facilities no longer had any such materials. Shortages of DMPA
leaflets were most pronounced in Baguio City, Surigao Sur, Iloilo City and South
Cotabato.

Figure 27
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Figure 28

These findings demonstrate that there is a need to improve the existing system for
distributing IEC materials about DMPA to the local level. In particular, DMPA
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reminder cards should be made available in all DMPA-dispensing facilities in order
to help women remember when their next reinjection is due. An adequate number
of leaflets should likewise be found in the facilities so as to assist in the campaign to
recruit a greater number of DMPA acceptors.
Shortages in IEC materials were generally small in the LGUs located closest to Metro
Manila (Quezon City, Pangasinan, Laguna) whereas they tended to be high in
peripheral areas like Surigao and South Cotabato.

This indicates that special

attention may have to be given to facilitating the flow of these materials to the less
accessible LGUs.

I. Number of First Injections and Reinjections: Pro-Rating Results

We have noted that the reported decrease in the number of first injections and
reinjections, specifically during the last six months of the observation period, has
been affected by the decline in the reporting rates of most of the LGUs. This being
the case, it will therefore be necessary to adjust for this factor if we are to come up
with an overall estimate of the number of first injections and reinjections. This may
be accomplished by a pro-rating exercise which assumes that those facilities which
did not file their monitoring report were nonetheless equally active in dispensing
DMPA as those that did submit the report (i.e., the method takes the average
number of injections and reinjections per facility for the reporting facilities and
applies this as well to all facilities which failed to submit their report).
Pro-rating of the number of injections was not carried out for all months prior to July
1994, since it was only by then that the trainings for the service providers were more
or less completed. The months July '94 - September '94 thereby become Quarter 1,
whereas October '94 - December '94 is Quarter 2, January '95 - March '95 is Quarter 3,
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April '95 - June '95 is Quarter 4, July '95 - September '95 is Quarter 5 and October '95 December '95 is Quarter 6.
The pro-rated number of first injections shown in Table 1 show a pattern similar to
that discussed earlier; i.e., that most LGUs have experienced a long-term decline in
DMPA acceptance. This was especially true for Pangasinan and South Cotabato,
which registered first injection levels during the Sixth Quarter that were less than
half as large as those obtained during the First Quarter.

In comparison,

proportionate declines between these same two quarters were least for the three
remaining LGUs from Mindanao -- Davao City, Davao del Sur and Surigao del Sur.
Table 1. Total Number of First Injections per Quarter by LGU (Pro-rated)
Q1

Q2

Q3

Q4

Q5

Q6

Baguio City
Quezon City
Pangasinan
Laguna
Iloilo City
Cebu
Davao City
Davao Sur
Surigao Sur
South Cotabato

470
1,735
4,980
1,233
164
3,159
583
2,427
590
1,938

309
1,165
3,716
906
173
2,478
579
1,768
661
1,246

226
1,288
3,255
1,118
216
2,571
681
1,780
591
1,372

239
1,025
2,618
926
92
2,034
628
1,393
563
1,090

205
1,102
2,129
757
67
1,094
537
1,459
617
871

251
952
1,930
668
88
1,725
510
2,400
575
854

All LGUs

17,279

13,001

13,098

10,578

9,648

9,953

Table 2 shows the number of reinjections as computed by the same pro-rating
procedure. As may be seen therein, Quezon City, Davao City and Surigao Sur all
showed consistently increasing trends. Most of the other LGUs also experienced an
upward movement although declines can be noted between the Fifth and Sixth
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Quarters in several cases. Laguna and Iloilo City are perhaps the most problematic
in this regard since these show declines for two succeeding quarters over the period
July to December 1995.

Table 2. Total Number of Reinjections per Quarter by LGU (Pro-rated)

Baguio City
Quezon City
Pangasinan
Laguna
Iloilo City
Cebu
Davao City
Davao Sur
Surigao Sur
South Cotabato
All LGUs

Q1

Q2

Q3

Q4

Q5

Q6

75
175
397
307
24
406
5
400
3
153

380
1,226
3,646
1,040
138
2,978
469
2,003
371
1,506

634
1,785
6,260
1,561
272
5,126
733
3,128
705
1,930

618
2,350
6,285
2,421
280
6,158
1,084
3,902
1,015
2,301

725
2,416
7,113
2,330
269
6,755
1,170
4,315
1,266
2,545

692
2,934
6,732
2,110
196
6,583
1,264
3,696
1,463
2,535

1,945

13,757

22,134

26,414

28,904

28,205

From the pro-rated number of first injections and reinjections, the average number
of injections dispensed per facility in each LGU was also ascertained. Table 3 shows
these figures. As may be noted therein, at least four LGUs (Baguio City, Quezon
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City, Davao City, and Surigao del Sur) showed generally increasing trends. In
comparison, stable or declining rates can be noted for Iloilo, Laguna, Pangasinan,
Cebu, Davao Sur and South Cotabato. Iloilo City and Laguna posted the highest
declines from the fourth to the last quarter with the average number of injections in
these two LGUs going down by 23.6 percent and 17.6 percent, respectively, at this
time.
The relatively poor performance noted on several of the indicators used in this study
for Laguna and Iloilo City is worthy of further comment, speculative as this may be.
In the former case it may be hypothesized that a lack of political support for the FP
program as a whole has weakened the DMPA reintroduction effort (the governor of
Laguna is a well-known critic of "artificial" forms of contraception). In Iloilo City, in
contrast, the major problem may be the presence of a medical/legal barrier in the
form of a local stipulation that husbands must sign a consent form before a married
woman can be injected with DMPA.
Table 3. Average Number of Monthly Injections Dispensed per Facility by LGU*

Baguio City
Quezon City
Pangasinan
Laguna
Iloilo City
Cebu
Davao City
Davao Sur
Surigao Sur
South Cotabato
All LGUs

Q1

Q2

Q3

Q4

Q5

Q6

10.69
12.32
5.23
6.70
2.11
6.15
4.29
6.20
6.05
5.58

13.51
14.49
6.15
6.64
3.08
7.73
7.28
8.36
5.61
7.28

16.86
18.18
7.62
6.73
4.52
10.49
9.43
10.18
5.40
8.53

16.80
19.74
6.86
7.44
3.35
10.89
11.41
10.83
6.39
8.48

18.24
20.57
7.08
6.81
3.03
11.45
11.38
11.81
7.56
8.50

18.49
22.73
6.64
6.13
2.56
10.99
11.83
12.37
8.18
8.43

6.03

7.34

8.93

8.98

9.36

9.11

* based on pro-rated results
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PROJECTED DMPA UTILIZATION BASED ON
THE STUDY RESULTS
The observed data on the

average monthly total injections from July 1994 to

December 1995 were compared to several theoretical models as a preliminary step
towards projecting the demand for DMPA from July 1995 to December 1998. In this
regard, three criteria were considered in deciding on which model to

use in

forecasting the DMPA demand:
1.

The model should explain or account for at least 80.0 per cent of the
variation in the observed data;

2.

All the independent variables in the model should be significant, i. e.,
all b coefficients are significantly greater than zero; and

3.

The projected values do not go far beyond the range of the observed
data.

A. The Models
There were seven models examined to determine initially which model best fit the
observed data on the average number of injections per month. These were (1) the
Simple Arithmetic Expansion Model, (2) the Simple Time Series Model, (3) the
Lagged Model, (4) the Sinusoidal Model, (5) the Learning Curve Model, (6) the
Learning Curve Cum Lagged Model, and (7) the Learning Curve Cum Sinusoidal
Model.
1. Model I: Simple Arithmetic Expansion Model
This model is expressed as follows:
Yi = Yi'
where:Yi = Average Monthly Total Injections
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Yi'= Weighted Average of Monthly Total Injections
= 8.30
Model I essentially assumes that there will be no change in DMPA injection levels
throughout the period in question. It was already used in Feb 1995 to forecast
DMPA requirements for 1995-1998. This was resorted to because of the limited data
available at that time on total injections. This model is not expected to give a good
fit to the data and is being shown for comparison with the other models.
2. Model II: Simple Time Series Model
This Model is as follows:
Yi = a + bXi + ei
where:Yi = Average Monthly Total Injections
Xi = Month:1, Jul '94;2, Aug, '94;..;18, Dec '95
ei = error

This model makes use of time (as measured by the ordinal ranking of the months in
question) as a predictor of average monthly total injections. As this is a simple linear
regression model, the extent to which the model explains the variation in the data is
measurable. It has a standard deviation of 0.80, which is a measurement of how far
the model is from the actual data. The "b" coefficient is significantly greater than
zero, i.e., the passage of time significantly explains the monthly pattern of total
injections. The Coefficient of Determination (R2) is 67.09 percent which means that
the model accounts for 67.09 per cent of the variation of the data.
3. Model III: Lagged Model
Yi = a + b1X1i + b2X2i + ei
where:Yi = Average Monthly Total Injections
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X1i = Month:1, Jul '94;2, Aug '94;..;18, Dec '95
X2i = Average Monthly Total Injections 3 Months Earlier

This model is Model II plus another variable, X2, the average number of injections
three months earlier. This additional term in the model captures the phenomenon of
women who have had their DMPA injections 3 months earlier returning for their
reinjections. In this case only X1, (i.e. month) is significantly related to Y, the average
monthly total injections. This model has a standard deviation of 0.57 and explains
84.44 per cent of the variation of the data on average monthly total injections.
4. Model IV: Sinusoidal Model
Yi = a + b1X1i + b2X2i + b3X3i + b4X4i + b5X5i + ei
where:Yi = Average Monthly Total Injections
X1i = t, Month: 1, Jul '94;2, Aug '94;..;18, Dec '95
X2i = Cos (2πt/3)
X3i = Sin (2πt/3)
X4i = t Cos (2πt/3)
X5i = t Sin (2πt/3)
This model consist of the time variable X1 and four variables with sine or cosine
terms, X2, X3, X4, and X5, which mathematically capture into the model the cyclical
phenomenon of women who have taken DMPA injections in a particular month
coming back for reinjections in the 4th month or after the 3rd month. However, we
again find in this case that only the time variable, X1, is found to be significantly
related to Y. The other four variables are not. This model has a standard deviation of
0.75 and explains 78.60 per cent of the variation in Y.
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5. Model V: Learning Curve Model
Yi = a + b(1 - 1/et) + error
where:Yi = Average Monthly Total Injections
e = Mathematical Constant Equal to 2.71928
t = Month:1, Jul '94;2, Aug '94;..;18, Dec '95
In this model the variable time, t, was transformed by the expression, (1-1/et). This
makes the effect of time on Y increasing during the initial time periods and then
plateauing to a certain level after some time, thus the name Learning Curve Model.
In the previous four models, Models I-IV, the effect of time on Y was always
increasing. The major predictor variable in this model (time transformed) turned out
to be significantly related to Y. The model has a standard deviation of 0.90 and
accounts for 58.99 per cent of the variation in Y.
6. Model VI: Learning Curve Cum Lagged Model
Yi = a + b1X1i + b2X2i + ei
where:Yi = Average Monthly Total Injections
e = Mathematical Constant Equal to 2.71928
t = Month:1, Jul '94;2, Aug '94;..;18, Dec '95
X1i = (1 - 1/et)
X2i = Average Total Injections 3 Months Earlier
This model incorporates to the Learning Curve Model within variable X1, whereas
the variable X2 captures the phenomenon of women coming back for reinjections 3
months after their latest injections. Both variables were found to be significantly
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related to Y. The model has a standard deviation of 0.54 and accounts for 85.91 per
cent of the variation in Y.

7. Model VII: Learning Curve Cum Sinusoidal Model
Yi = a + b1X1i + b2X2i + b3X3i + b4X4i + b5X5i + ei
where:Yi = Average Monthly Total Injections
e = Mathematical Constant Equal to 2.71928
t = Month:1, Jul '94;2, Aug '94;..;18, Dec '95
X1i = (1 - 1/et)
X2i = Cos (2πt/3)
X3i = Sin (2πt/3)
X4i = t Cos (2πt/3)
X5i = t Sin (2πt/3)
This model is similar to Model IV, the Sinusoidal Model except that the time
variable, t, was transformed into the variable X1 through the expression (1 - 1/et). It
again turns out, though, that only this variable is significantly related to Y. This
model has a standard deviation of 0.93 and explains 66.65 per cent of the variation in
Y.
The graphical representation of the models for mean total injections per facility are
shown in Figures 29, to 35. Their major parameters (standard deviation, coefficient
of determination or R2, significant independent variables, and the F-Ratio for each
model) are shown in Table 4.
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Table 4. Standard Deviation, R2, Number of Independent Variables,
Significant Variables and F-Ratio for Seven Models of DMPA Demand
INTEGRATED
MODELS:
TOTAL INJECTIONS

Std
Dev

R2

No. of
Independent
Variables

Significant
Variables

F-Ratio

I. Simple Arithmetic Expansion
II. Simple Time Series

0.8058 67.09

1

X

32.6106 **

III. Lagged

0.5721 84.44

2

X1

40.7106 **

IV. Sinusoidal

0.7501 78.60

5

X1

37.6253 **

V. Learning Curve

0.8993 58.99

1

X

23.0189 **

VI. Learning Cum Lagged

0.5445 85.91

2

VII. Learning Curve
Cum Sinusoidal

0.9365 66.65

5

X1, X2
X1

45.7275 **
4.7970 *

NOTE: * Significant (at 0.05 level)
** Highly Significant (at 0.01 level)

B. The Forecast
Forecasts were made of the average monthly DMPA requirements of Phases I to III
using the integrated models. These are shown in Figures 36, 37 and 38. The details
are shown in Appendix A.
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Figure 33
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DMPA Reintroduction
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to use in formally

for DMPA from 1995 to 1998 for the three phases of the

Program,

out to be the most appropriate.

Model VI: Learning Curve Cum Lagged Model came

Its two independent variables were both highly significant

and accounted for 85.91 per cent of the variation in Y _

In the forecasts
optimistic

of average

DMPA

total injections,

forecasts going up from 9.4 in December

which is a level much higher

of average monthly

in average monthly

Models

II-IV had very

1995 to 15.2 in December

than that ever achieved during the observation

Those of Models V-VII avoided this
low level

monthly

problem
except

1997,
period.

that Model V exhibited a relatively

injections and Model VII showed very wide fluctuations

total injections.

Model I, on the other hand, is too simplistic.
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With Model VI as the basis, the total DMPA demand was estimated by multiplying
the forecasted average monthly DMPA total injections by the total number of health
facilities participating in the program. For 1995 the DMPA requirements was
estimated to be 615,021 vials; for 1996, 1,091,104 vials; for 1997, 1,112,618 vials; and
for 1998, 1,112,810 vials or a grand total of 3,931,553 vials (See Table 5). The number
of facilities is expected to expand from 1,379 in Phase I to 4,097 in Phase II and 4,712
in Phase III.
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Table 5. Projected DMPA Demand 1995-1998
Based on Targetted No. of Facilities

Year

Phase I
Phase II
Phase III
Total

No. of Facilities

DMPA Demand

Total

1995

1996

1997

1998

1,379
4,097
4,712

146,730
387,487
80,804

151,099
446,960
493,045

150,629
447,501
514,488

150,625
447,506
514,579

599,083
1,729,454
1,603,016

10,188

615,021

1,091,104

1,112,618

1,112,810

3,931,553
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The Consumption Trend Report on DMPA as of May 23 1996 by the CDLMIS
indicate a DMPA utilization of 355,945 vials in 1995. The current estimate of DMPA
utilization for 1995 using Model VI totals 615,021 vials or 279,176 vials more.
This would have been easily reconciled, if the information on the number of facilities
actually dispensing in Phase II and Phase III were available. Unfortunately, this was
not the case. The CDLMIS Consumption Trend Report was based on returns from
supply points and not from DMPA-dispensing facilities. Moreover, the reports on
training of providers do not indicate the corresponding number of health facilities
that they will be servicing.
To reconcile the projection figures and the Consumption Trend Report figures, the
number of DMPA-dispensing facilities was derived by multiplying the number of
trained DMPA providers in Phase II and Phase III by 0.7889, the ratio of the number
of DMPA- dispensing facilities and number of DMPA-trained providers in Phase I.
This could be interpreted to mean that for every 1000 DMPA-trained providers there
will be 789 DMPA-dispensing facilitiies. Thus, the number of DMPA-dispensing
facilities in Phase II and Phase III are 3,518 and 1,617 respectively (See Table 6).
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Table 6. Number of DMPA-Trained Providers and
Estimated Number of DMPA Facilities, Phase II and Phase III

*
**
***

Funding Agency

Phase II*

PhaseIII**

UNFPA
USAID/EDF

2,600
1,829

1,098
951

Total

4,429

2,099

No. of Facilities***

3,518

1,617

From FPS Table: DMPA Training Accomplishment - Phase II
From Project Management Team, UNFPA Table: DMPA Training by Provinces ( OctDec 1995) and MSH Table: Number of Persons Trained in DMPA.
From Phase I data of 0.7889 DMPA-Dispensing Facility per DMPA-Trained Provider or
789 facilities per 1,000 trained provider.

The revised projection of DMPA demand using the estimated actual number of
DMPA- dispensing facilities are 474,077 vials in 1995; 697,821 in 1996; 711,443 in
1997 and 711,509 in 1998 (See Table 7).
Inasmuch as the training of DMPA providers is not yet over and therefore the
number of DMPA-dispensing facilities can increase during the year, the actual
DMPA utilization for this year and succeeding years would range as follows:
1996

697,821 - 1,091,104 vials

1997

711,443 - 1,112,618 vials

1998

711,509 - 1,112,810 vials
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Table 7. Projected DMPA Demand 1995-1998 Based on
Estimated Number of DMPA-Dispensing Facilities
Year

No. of Facilities

DMPA Demand

Total

1995

1996

1997

1998

Phase I
Phase II
Phase III

1,379
3,518
1,617

146,730
305,741
21,606

151,099
383,794
162,928

150,629
384,259
176,555

150,625
384,263
176,621

599,083
1,458,057
537,710

Total

6,514

474,077

697,821

711,443

711,509

2,594,850
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Figure 37
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SUMMARY AND POLICY IMPLICATIONS

Beginning in 1994 the injectable contraceptive Depo-medroxy Progesterone Acetate (DMPA)
became available on a pilot basis in ten Local Government Units (LGUS) throughout the
Philippines. These included Baguio City, Quezon City, Laguna, Pangasinan, Iloilo City, Cebu,
Davao City, Davao del Sur, South Cotabato and Surigao del Sur. During this period the
Population Council, in collaboration with the Department of Health, conducted an operations
research study which collected monitoring data on program implementation and impact in the
ten participating LGUS. Data were collected at this time on both the adoption of DMPA (first
injections) and continuing use (reinjections) of this family planning method, as well as on the
availability of DMPA supplies and IEC materials. The period of observation extended from
April 1, 1994 to December 31, 1995.

A total of 157,662 DMPA injections were reported to have been dispensed in the ten pilot
LGUs within the 21-month observation period. About forty percent (39.8 %) were given as first
injections to new DMPA acceptors while 61.2 percent were given

as reinjections. During the first three quarters, the total number of injections given
out increased rapidly (from about 19,000 to 35,000 injections per quarter). Since then
the number of reported injections stabilized at approximately 37,000 to 38,000
injections for every three-month period of observation.
First injections declined consistently during the 21-month period covered by the
survey. The reported number of reinjections increased steadily up to the sixth
quarterly round of data collection, thereafter declining slightly.
Altogether, the pilot LGUs averaged about 3 or 4 injections per facility per month
during the first quarter. This increased to about 6 or 7 during the second quarter
and then to 7 or 8 injections during the third quarter. During the last twelve months
of the period covered by this report, approximately nine DMPA injections were
being disposed per reporting facility each month.

For the whole 21-month

observation period, the program dispensed an average of 7.5 injections per reporting
facility per month.
The different LGUs varied considerably with regard to their performance in this
regard.

For the last year of observation, Quezon City and Baguio City were

consistently dispensing an average of more than 15 injections per reporting facility
per month. Pangasinan, Laguna and ,in particular, Iloilo City were all faring much
more poorly, with the Iloilo City average typically coming to only about three
injections per month.
As a whole, the sample cities averaged 11.6 injections per reporting facility per
month while the provinces averaged 7.6 injections per reporting facility per month.
The overall reinjection rate was estimated at 71.3 percent. Of the 130,620 reinjections
expected to be given between October 1994 to December 1995, a total of only 93,123
were actually dispensed.
Of the 62,736 DMPA acceptors in the ten pilot LGUs, only 25,175 were still using
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DMPA as of December 31, 1995. The overall proportion of current users as of the
end of the study period was therefore about 40 percent.
Of the estimated 1.9 million MWRA in the ten pilot LGUs, 3.3 percent had accepted
DMPA during the observation period while 1.4 percent of these acceptors were still
using the method as of December 31, 1995.
Data were also collected on affiliated DMPA supplies. By the end of the observation
period an average of 37 vials and syringes per facility were on stock for the overall
sample. This statistic was again found to vary considerably among the different
LGUs, being highest for Quezon City, Cebu and Baguio City and lowest in three of
the Mindanao Provinces (South Cotabato, Davao Sur, Surigao Sur) as well as in
Pangasinan.
A little less than a third of the pilot facilities had run out of reminder cards as of the
end of the observation period. A similar proportion had no DMPA leaflets as of that
same date. LGUs faring most poorly in this regard included Surigao Sur and South
Cotabato (for both reminder cards and leaflets), Cebu (for reminder cards only) and
Baguio City and Iloilo City (for leaflets only).
The reported decrease in the number of first injections and reinjections during the
last six months of the observation period has been affected by the decline in the
reporting rates of most of the LGUs. Estimates of the number of first injections and
reinjections were made using a pro-rating procedure. These showed that a longterm trend towards a declining number of first injections has been underway in the
study area for approximately the last four quarters under observation. Declines
were highest in Pangasinan and South Cotabato. Declines were least in Davao City,
Davao Sur and Surigao Sur, all of which represent LGUs from Mindanao.
Data from the study were used to project the total (nationwide) demand for DMPA
over the period July 1995 to December 1998. Seven different mathematical models
were compared for this purpose with the one which was best able to predict actual
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time trends during the data collection period (July 1994- December 1995) being
eventually selected. This turned out to be a "Learning Curve Cum Lagged Model"
which is based upon two major assumptions: first, that DMPA adoption will follow
a "learning curve" pattern (increasing rapidly at first and then plateauing to a certain
level after some time) and, second, that the total number of injections given three
months earlier can serve as an additional predictor variable (since reinjections are
due after a time lag of three months). The overall fit between this model and the
pro-rated injection estimates was quite good (R2 = 0.86).
The subsequent projection procedure was made somewhat difficult by reason of the
fact that the DOH has not collected any information on the total number of health
facilities in the country which have become equipped to dispense DMPA. Two
different estimates of the number of such facilities were obtained. Together these
yielded a range for DMPA demand which may be projected for the next three years.
These were approximately 700,000 to 1,100,000 vials of DMPA for each of the three
years being considered (1996 to 1998) for an overall total of 2,100,000 to 3,200,000
vials.

Policy Implications:
Some of the major implications of the study for the current DMPA reintroduction
program are listed below:
1.

Data from this study have already been used to project future DMPA
demand in the ten LGUs originally participating in the reintroduction effort.
As the program's coverage is extended in an ever widening circle (with all
LGUs set to participate by early 1996), future demand for DMPA can now be
estimated for the nation as a whole using data from the study.
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2.

With an average of 37,000 injections per quarter, it may be estimated that
DMPA was being used by about two percent of all married women of
reproductive age in the ten LGUs under observation. As such, the method
appears to be exerting a moderately positive impact upon overall levels of
contraceptive use.

3.

The considerable inter-LGU variation found for the number of DMPA users
per facility indicates that programmatic factors may be involved here. For
example, medical/legal barriers to DMPA use seem to have brought about
the low acceptance rates found for Iloilo City whereas a lack of high-level
political support was probably affecting the reintroduction campaign in
Laguna. Continued monitoring of the different LGUs and follow-up of those
with particularly low user rates are suggested.

4.

An adequate supply of DMPA vials and syringes was found in most of the
participating health centers. A similar conclusion could not be reached,
however, for the case of DMPA reminder cards and leaflets. Mechanisms for
ordering additional copies of these materials should be set in place and
implemented thoroughly.

5.

There is some evidence that the present logistical system is operating more
efficiently in the case of LGUs located near the core region of Metro Manila.
Additional efforts may be needed to reach health centers found in peripheral
regions, e.g. Southern Mindanao.

6.

Only about 3.3 percent of the MWRA have ever accepted DMPA. A more
vigorous campaign to inform women about the availability of this method
seems called for, especially in light of the trend towards a declining number
of new DMPA acceptors which has been noted during the last twelve months
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of the study.
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Appendix A

1. Model I: Simple Arithmetic Expansion Model
This model is expressed as follows:
Yi = Yi'
where:
Yi = Average Monthly Total Injections
Yi'= Weighted Average of Monthly Total Injections
= 8.30
2. Model II: Simple Time Series Model
This Model is as follows:
Yi = a + bXi + ei
where:
Yi = Average Monthly Total Injections
Xi = Month:1, Jul '94;2, Aug, '94;..;18, Dec '95
ei = error
3. Model III: Lagged Model
Yi = a + b1X1i + b2X2i + ei
where:
Yi = Average Monthly Total Injections
X1i = Month:1, Jul '94;2, Aug '94;..;18, Dec '95
X2i = Average Monthly Total Injections 3 Months Earlier
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4. Model IV: Sinusoidal Model
Yi = a + b1X1i + b2X2i + b3X3i + b4X4i + b5X5i + ei
where:
Yi = Average Monthly Total Injections
X1i = t, Month: 1, Jul '94;2, Aug '94;..;18, Dec '95
X2i = Cos (2πt/3)
X3i = Sin (2πt/3)
X4i = t Cos (2πt/3)
X5i = t Sin (2πt/3)
5. Model V: Learning Curve Model
Yi = a + b(1 - 1/et) + error
where:
Yi = Average Monthly Total Injections
e = Mathematical Constant Equal to 2.71928
t = Month:1, Jul '94;2, Aug '94;..;18, Dec '95
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6. Model VI: Learning Curve Cum Lagged Model
Yi = a + b1X1i + b2X2i + ei
where:
Yi = Average Monthly Total Injections
e = Mathematical Constant Equal to 2.71928
t = Month:1, Jul '94;2, Aug '94;..;18, Dec '95
X1i = (1 - 1/et)
X2i = Average Total Injections 3 Months Earlier
7. Model VII: Learning Curve Cum Sinusoidal Model
Yi = a + b1X1i + b2X2i + b3X3i + b4X4i + b5X5i + ei
where:
Yi = Average Monthly Total Injections
e = Mathematical Constant Equal to 2.71928
t = Month:1, Jul '94;2, Aug '94;..;18, Dec '95
X1i = (1 - 1/et)
X2i = Cos (2πt/3)
X3i = Sin (2πt/3)
X4i = t Cos (2πt/3)
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X5i = t Sin (2πt/3)
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